What researchers published on Chronic myeloid leukaemia
900 papers, newest first.
Showing 20 of 900
Not labelled yetPharmacological SOS1 inhibitor BI-3406 synergizes with BCR::ABL1 TKIs reducing leukemia stem cells and overcoming imatinib resistance in CML.Cell death & disease
Not labelled yetDifferential regulation of PRSS57 by tyrosine kinase inhibitors and ATRA in myeloid leukaemia cells: an in vitro study.Journal of applied genetics
Not labelled yetInvestigation of selected MiRNA as potential biomarker in chronic myeloid leukemia patients.Medicine and pharmacy reports
Not labelled yetCapillary dried plasma microsampling: A novel approach for therapeutic drug monitoring of tyrosine kinase inhibitors in chronic myeloid leukemia patients by UPLC-MS/MS.Journal of pharmaceutical and biomedical analysis
Not labelled yetCorrection: Target inhibition of CBP induced cell senescence in BCR-ABL- T315I mutant chronic myeloid leukemia.Frontiers in oncology
Not labelled yetDasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: long-term efficacy and endocrine analysis.Blood advances
Case reportProlonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms.Annals of hematology
Not labelled yetAptamers in cancer research: Focus on leukemia.Chinese medical journal
Not labelled yetA novel SLTM::RUNX1 acquired during CML progression and the clinical significance of concurrent BCR::ABL1 and RUNX1 rearrangements in Ph-positive leukemia.Cancer genetics
Not labelled yetRelcobatinib, a highly selective ATP-competitive ABL1 tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.Leukemia
Not labelled yetProspective Evaluation of Hepatitis B Virus Reactivation in Cancer Patients Receiving Tyrosine Kinase Inhibitors.Journal of medical virology
ReviewEmerging BCR::ABL1 inhibitors in chronic myeloid leukemia: current advances and future directions.International journal of hematology
Case reportChronic Myeloid Leukemia Progressing to Early T-Cell Precursor Lymphoblastic Blast Phase Following Treatment Default: An Integrated Morphologic, Immunophenotypic, Cytogenetic, and Molecular Case Report.Cureus
Not labelled yetANGPT1-based targeted drug screening: Identification of Tasosartan and its activity against tyrosine kinase inhibitor resistance in chronic myeloid leukemia.The Journal of international medical research
Not labelled yetAssessment of Interpatient and Intrapatient Variability of Dasatinib and Imatinib Concentrations in Patients With Chronic Myeloid Leukemia via Volumetric Absorptive Microsampling at Home.Therapeutic drug monitoring
Case reportBone Marrow Aplasia Under Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Rare and Unpredictable Complication.Cureus
Not labelled yetTreatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group.Annals of hematology
Review[Treatment strategies for chronic-phase chronic myeloid leukemia in 2026].[Rinsho ketsueki] The Japanese journal of clinical hematology
ReviewChronic Myeloid Leukemia Beyond BCR::ABL1 Inhibition: Resistance Mechanisms and Emerging Therapeutic Modalities.Pharmaceuticals (Basel, Switzerland)
Not labelled yetLeukostasis-related retinopathy as the initial presentation of chronic-phase chronic myeloid leukaemia.BMJ case reports